Skip to main content
. 2021 Dec 18;94(4):1617–1626. doi: 10.1002/jmv.27512

Figure 3.

Figure 3

Network plot of eligible comparisons for all‐cause mortality (A), and the TEAEs ratio (B) of medications in patients with severe COVID‐19. ALA, α‐lipoic acid; COVID‐19, coronavirus disease 2019; SOC, standard of care; TEAEs, treatment‐emergent adverse events